OVID today
$2.54-$0.01 (-0.39%)close Nov 13, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns down below $2.02
Key levels
Resistance$2.87
Resistance$2.65
Support$2.35
Support$2.10
Latest news & SEC filings
EarningsOvid Therapeutics Posts Q3 2026 Results, Gives Business Update
SEC FilingOvid Therapeutics Inc. filed a shelf registration for future offerings (Form S-3)
EarningsOvid Therapeutics posts quarterly loss of $0.10 per share, wider than $0.09 estimate
SEC FilingOvid Therapeutics Inc. filed a report on a major company event (Form 8-K)
All OVID news →About Ovid Therapeutics
Ovid Therapeutics is a biopharmaceutical company that creates oral and injectable treatments aimed at central nervous system conditions. Its pipeline targets excessive neuron firing, with clinical programs for hard-to-treat focal seizures, developmental and epileptic encephalopathies, psychosis linked to Lewy body dementia and Parkinson's, and schizophrenia. The company licenses compounds and works with academic researchers, mainly in the United States.
Based on the company's 10-K filed Mar 18, 2026.
Nasdaq · Healthcare
Ovid Therapeutics Inc. (OVID)
What Is the Price Target for OVID?
SEPT Low Target
$5.00
SEPT Mid Target
$6.00
SEPT High Target
$9.00
Analyst Consensus
$6.00
Is OVID a Buy or Sell Right Now?
Thesis
- •Revenue growing 1181.3% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for OVID.
Start Free Trial →Is OVID Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$6.00
27
Moat Score
NONE
4/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with OVID?
Insider Signal
NEUTRAL
0 buys / 2 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →OVID Growth Story
Revenue YoY
1181.3%
3yr Revenue CAGR
69.0%
EPS Growth YoY
N/A
FCF Growth YoY
31.6%
Revenue Trend
ACCELERATING
Dark Pool Trades for OVID
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for OVID, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:10:57 | $2.54 | 1,924 | $$5K | BUY |
| 21:00:20 | $2.54 | 3,700 | $$9K | SELL |
| 21:00:20 | $2.54 | 12,200 | $$31K | SELL |
| 20:59:47 | $2.55 | 1,200 | $$3K | BUY |
| 20:59:41 | $2.54 | 1,500 | $$4K | BUY |
5 dark pool trades shown · $$52K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Ovid Therapeutics Inc. (OVID) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (6 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →OVID — frequently asked questions
What is OVID stock price today?
Ovid Therapeutics Inc. (OVID) is at $2.54, down 0.39% (-$0.01) at the Nov 13, 2026 close.
Why is OVID stock moving today?
Latest OVID news — Nov 10, 2026: Ovid Therapeutics Posts Q3 2026 Results, Gives Business Update · Nov 10, 2026: Ovid Therapeutics Inc. filed a shelf registration for future offerings (Form S-3)
Why did OVID stock move on Nov 10, 2026?
Ovid Therapeutics shares closed at $2.80, up 1.45% on volume of about 2.29 million shares, even as the company reported a wider-than-expected quarterly loss of $0.10 per share versus the $0.09 loss analysts projected. The biopharma also disclosed a shelf registration (Form S-3) allowing future securities offerings, a move that can pressure shares through potential dilution.
What is the OVID price target?
The average analyst price target for OVID is $6.00, ranging from $5 to $9, based on 6 analysts. Latest: Wolfe Research initiates on Oct 15, 2026.
What do analysts rate OVID?
Analyst ratings for OVID: 0 Buy, 10 Hold, 0 Sell — consensus Hold.
Did OVID beat earnings?
OVID last reported on Nov 11, 2026: EPS -$0.10 vs -$0.09 expected — a miss of 11.1%.
Does OVID pay a dividend?
OVID does not currently pay a dividend.
What are OVID support and resistance levels?
Support: $2.35, $2.10, $1.66. Resistance: $2.65, $2.87, $3.09.
What are insiders doing with OVID?
Insider activity: NEUTRAL, 0 buys and 2 sells in the last 90 days.
What is the latest news on OVID?
Nov 10, 2026: Ovid Therapeutics Posts Q3 2026 Results, Gives Business Update · Nov 10, 2026: Ovid Therapeutics Inc. filed a shelf registration for future offerings (Form S-3) · Nov 10, 2026: Ovid Therapeutics posts quarterly loss of $0.10 per share, wider than $0.09 estimate